The Effect of the Concurrent Use of Angiotensin-Converting Enzyme Inhibitors or Receptor Blockers on Toxicity and Outcomes in Patients Treated with Radiotherapy: A Systematic Revie... by Wan-Chuen Liao, Hala Shokr, Corinne Faivre-Finn, Clare Dempsey, Kaye Janine Williams, Li-Chia Chen

“…ACEI users exhibited a 50% reduction in the risk of ≥grade 2 radiation pneumonitis (OR: 0.50, 95%CI: 0.32–0.77) in lung cancer and significant reductions in the odds of proctitis (80%, OR: 0.20, 95%CI: 0.12–0.33), haematuria (75%, OR: 0.25, 95%CI: 0.16–0.41), and rectal bleeding (61%, OR: 0.39, 95%CI: 0.30–0.51) in prostate cancer. ACEI/ARB users showed reduced symptomatic radiation necrosis in brain metastases and better 6-month functional independence in supratentorial glioblastoma. …”
Get full text

The Effect of Steep Trendelenburg Positioning on Retinal Structure and Function during Robotic-Assisted Laparoscopic Procedures by Kazuyuki Hirooka, Kaori Ukegawa, Eri Nitta, Nobufumi Ueda, Yushi Hayashida, Hiromi Hirama, Rikiya Taoka, Yuma Sakura, Mari Yamasaki, Hiroyuki Tsunemori, Mikio Sugimoto, Yoshiyuki Kakehi

“…Robotic-assisted laparoscopic radical prostatectomy (RALP) has become a standard treatment choice for localized prostate cancer. RALP requires a steep Trendelenburg position, which leads to a significant increase in intraocular pressure (IOP). …”
Get full text

Accuracy of algorithms to identify patients with a diagnosis of major cancers and cancer-related adverse events in an administrative database: a validation study in an acute care h... by Takashi Fujiwara, Yasuyuki Okumura, Hironobu Tokumasu, Takashi Kanemitsu, Kosei Tajima, Akinori Yuri, Masahiro Iwasaku

“…The sensitivity and positive predictive value (PPV) with 95% CIs were calculated.Participants The validation cohort included patients with lung (n=2257), breast (n=1121), colorectal (n=1773), ovarian (n=216) and bladder (n=575) cancer who visited the hospital between January 2014 and December 2018, and those with prostate cancer (n=3491) visiting between January 2009 and December 2018, who were identified using EMRs.Outcomes Key outcomes included primary diagnosis, deaths and AEs.Results For primary diagnosis, sensitivity and PPV for the respective cancers were as follows: lung, 100.0% (96.6 to 100.0) and 81.0% (74.9 to 86.2); breast, 100.0% (96.3 to 100.0) and 74.0% (67.3 to 79.9); colorectal, 100.0% (96.6 to 100.0) and 80.5% (74.3 to 85.8); ovarian, 89.8% (77.8 to 96.6) and 75.9% (62.8 to 86.1); bladder, 78.6% (63.2 to 89.7) and 67.3% (52.5 to 0.1); prostate, 100.0% (93.2 to 100.0) and 79.0% (69.7 to 86.5). …”
Get full text

Application of raman spectroscopy in the non-invasive diagnosis of urological diseases via urine by Ailiyaer Ainiwaer, ShuWen Sun, Ayinuer Bohetiyaer, Yuchao Liu, Yufeng Jiang, Wentao Zhang, JingCheng Zhang, Tianyuan Xu, Hanyang Chen, Xudong Yao, Chengyou Jia, Yang Yan

“…Methods: We searched PubMed, Web of Science, and Google Scholar using 'raman,' 'bladder,' 'kidney,' 'prostate,' 'cancer,' 'infection,' 'stone or urinary calculi,' and 'urine or urinary,' along with 'AND' and 'OR' to refine our search. …”
Get full text

Changes in cancer incidence and stage during the COVID-19 pandemic in 2020–2021 in the Nordic countries by Anna Johansson, Anna Skog, Tom Børge Johannesen, Tor Åge Myklebust, Simon M. Kønig, Charlotte Wessel Skovlund, Lina Steinrud Mørch, Søren Friis, Marnar Fríðheim Kristiansen, David Pettersson, Eva María Gudmundsdóttir, Nanna Margrét Kristinsdóttir, Helgi Birgisson, Sandra Irenaeus, Johan Ahlgren, Mats Lambe, Elli Hirvonen, Janne Pitkäniemi, Giske Ursin

“…Stage I breast cancer incidence declined during 2020 in Denmark/Norway/Sweden, with some catch-up in stage II incidence in 2021. Prostate cancer rates declined in Denmark/Finland/Norway/Sweden during 2020–2021, while melanoma rates declined in Finland in 2020. …”
Get full text

Phase 1, open-label, dose-escalation study on the safety, pharmacokinetics, and preliminary efficacy of intravenous Coxsackievirus A21 (V937), with or without pembrolizumab, in pat... by Christy Ralph, Sumati Gupta, Matthew Zibelman, Brendan D Curti, Kevin J Harrington, Steven J O'Day, Andrew G Hill, David C Campbell, Gavin M Wright, David E Gerber, Jonathan E Rosenberg, Jaime R Merchan, Charles M Rudin, Hardev S Pandha, Wallace L Akerley, Daphne Day, Timothy D Clay, Ross R Jennens, Yixin Ren, Emmett V Schmidt, Lisa Guttman

“…This phase 1 study evaluated intravenous V937±pembrolizumab in patients with advanced solid tumors.Methods Patients had advanced non-small cell lung cancer (NSCLC), urothelial cancer, metastatic castration-resistant prostate cancer, or melanoma in part A (V937 monotherapy), and metastatic NSCLC or urothelial cancer in part B (V937+pembrolizumab). …”
Get full text

Liposomal encapsulation of cholecalciferol mitigates in vivo toxicity and delays tumor growth by Miriam Ezcurra-Hualde, Miriam Ezcurra-Hualde, Sara Zalba, Sara Zalba, Ángela Bella, Ángela Bella, Leire Arrizabalaga, Leire Arrizabalaga, Aline Risson, Aline Risson, Román García-Fuentes, Román García-Fuentes, Celia Gomar, Celia Gomar, Nuria Ardaiz, Nuria Ardaiz, Virginia Belsue, Virginia Belsue, David Ruiz-Guillamon, David Ruiz-Guillamon, Alejandro Serrano-Alcaide, Alejandro Serrano-Alcaide, Ainara Salgado, Ainara Salgado, Fernando Aranda, Fernando Aranda, Maria J. Garrido, Maria J. Garrido, Pedro Berraondo, Pedro Berraondo, Pedro Berraondo

“…In vitro gene expression modulation was evaluated in monocytic THP-1 cells, and antiproliferative effects were assessed in HT29 (colorectal), BT474 (breast), and TRAMP-C1 (prostate) cancer cell lines. In vivo antitumor efficacy and toxicity were tested in a mouse model with subcutaneously implanted MC38 tumors. …”
Get full text

Identification of new candidate genes for the hereditary predisposition to uveal melanoma: IGCMU trial by Mélanie Godiveau, Mélanie Godiveau, Mélanie Godiveau, Angeline Ginzac, Angeline Ginzac, Angeline Ginzac, Yannick Bidet, Yannick Bidet, Flora Ponelle-Chachuat, Flora Ponelle-Chachuat, Maud Privat, Maud Privat, Xavier Durando, Xavier Durando, Xavier Durando, Xavier Durando, Mathias Cavaillé, Mathias Cavaillé, Mathis Lepage, Mathis Lepage

“…Epidemiological studies have suggested an increased risk of prostate cancer, thyroid cancer, and leukemia among patients with UM, indicating potential unidentified genetic predispositions. …”
Get full text

Reporting and representation of participant race and ethnicity in phase III clinical trials for solid tumors by Tianyi Wang, Dinorah J Villanueva, Ambily Banerjee, Dina Gifkins

“…Compared with SEER data, the percentages were lower for Asian/Pacific Islander across all cancers, Black/African American in breast and prostate cancers, American Indian or Alaska Native in colorectal, breast, and prostate cancers in US solely trials.Conclusions Reporting and enrollment of racial and ethnic minorities in trials remain inadequate but improving. …”
Get full text

Lung Cancer: A Classic Example of Tumor Escape and Progression While Providing Opportunities for Immunological Intervention by Martin R. Jadus, Josephine Natividad, Anthony Mai, Yi Ouyang, Nils Lambrecht, Sandor Szabo, Lisheng Ge, Neil Hoa, Maria G. Dacosta-Iyer

“…Immunotherapy is making inroads towards effectively treating other fatal cancers, such as melanoma, glioblastoma multiforme, and castrate-resistant prostate cancers. This paper will cover the escape mechanisms of bronchogenic lung cancer that must be overcome before they can be successfully treated. …”
Get full text

The Immune Response to Tumors as a Tool toward Immunotherapy by F. Pandolfi, R. Cianci, D. Pagliari, F. Casciano, C. Bagalà, A. Astone, R. Landolfi, C. Barone

“…Herein we will review some of the recent achievement of immunotherapy in such aggressive cancers as melanoma, prostatic cancer, colorectal carcinoma, and hematologic malignancies. …”
Get full text

Emerging Lung Cancer Therapeutic Targets Based on the Pathogenesis of Bone Metastases by Moses O. Oyewumi, Adnan Alazizi, Daniel Wehrung, Rami Manochakian, Fayez F. Safadi

“…Each year, more people die of lung cancer than of colon, breast, and prostate cancers combined. It is widely accepted that tumor metastasis is a formidable barrier to effective treatment of lung cancer. …”
Get full text

Role of gp91phox Homolog Nox1 in Induction of Premalignant Spindle Phenotypes of HPV 16 E6/E7—Immortalized Human Keratinocytes by Walee Chamulitrat

“…While Nox1 has been shown to be expressed in human colon and prostate cancers, however, limited studies have demonstrated the involvement of Nox1 in an early step of cell transformation. …”
Get full text

Polymyalgia Rheumatica Revealing a Lymphoma: A Two-Case Report by Frank Verhoeven, Xavier Guillot, Mickaël Chouk, Clément Prati, Daniel Wendling

“…PET-CT revealed bursitis of the hips and the shoulders, no prostatic cancer recurrence, and a metabolically active iliac lymphadenopathy whose pathologic exam concluded to a low grade follicular lymphoma. …”
Get full text

Improving neuroendocrine tumor treatments with mathematical modeling: lessons from other endocrine cancers by John Metzcar, Rachael Guenter, Yafei Wang, Kimberly M Baker, Kate E Lines

“…Causal or mechanistic mathematical modeling is widely deployed in disease areas such as breast and prostate cancers, aiding the understanding of observations and streamlining in vitro and in vivo modeling efforts. …”
Get full text

Association between NFKB1 −94ins/del ATTG Promoter Polymorphism and Cancer Susceptibility: An Updated Meta-Analysis by Xiao Yang, Pengchao Li, Jun Tao, Chao Qin, Qiang Cao, Jinbao Gu, Xiaheng Deng, Jun Wang, Xuzhong Liu, Zijie Wang, Bian Wu, Min Gu, Qiang Lu, Changjun Yin

“…Stratified analyses revealed a significant association between the polymorphism and ovarian, oral, and prostate cancers. Similar results were determined in an Asian population and not in a Caucasian population. …”
Get full text

Identification and validation of a novel autoantibody biomarker panel for differential diagnosis of pancreatic ductal adenocarcinoma by Metoboroghene O. Mowoe, Metoboroghene O. Mowoe, Hisham Allam, Joshua Nqada, Marc Bernon, Karan Gandhi, Sean Burmeister, Urda Kotze, Miriam Kahn, Christo Kloppers, Suba Dharshanan, Zafirah Azween, Pamela Maimela, Paul Townsend, Eduard Jonas, Jonathan M. Blackburn, Jonathan M. Blackburn

“…Specifically, we quantified the serological AAb profiles of 94 PDAC, chronic pancreatitis (CP), other pancreatic- (PC) and prostate cancers (PRC), non-ulcer dyspepsia patients (DYS), and healthy controls (HC).ResultsCombinatorial ROC curve analysis on the training cohort data from the cancer antigen microarrays identified the most effective biomarker combination as CEACAM1-DPPA2-DPPA3-MAGEA4-SRC-TPBG-XAGE3 with an AUC = 85·0% (SE = 0·828, SP = 0·684). …”
Get full text